The BBVA Foundation, Massachusetts General Hospital Cancer Center and Vall d’Hebron Institute of Oncology have signed a collaboration agreement to support the development of personalized cancer therapies through biomarker research. Over the next five years, the program will work towards the dual goal of discovering new drug treatments and improving or optimizing the use of existing drugs.
